NCT01330901View on ClinicalTrials.gov

Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

April 30, 2013

Study Completion Date

May 31, 2013

Conditions
Ankylosing Spondylitis
Interventions
DRUG

Ustekinumab

Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16

Trial Locations (1)

12203

Department of Rheumatology, Charité - Campus Benjamin Franklin, Berlin

All Listed Sponsors
lead

Charite University, Berlin, Germany

OTHER

NCT01330901 - Ustekinumab for the Treatment of Patients With Active Ankylosing Spondylitis | Biotech Hunter | Biotech Hunter